RxDoctor Payments Data

Diana Roy, DO

Family Practice · Plano, TXNPI 1609403047

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 84 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 22.0% — the pattern of someone who eats at a lot of different presentations. Among family practice clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,437in general payments, 2019–2025

Across 84 payments — averaging $17.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$316
  • AbbVie$197
  • AstraZeneca$197
  • Exact Sciences$77
  • Lilly USA, LLC$63
  • Boehringer Ingelheim$63
  • plus $522 from 16 others

What the payments were for

  • Food & beverage$1,437100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,437 in reported general payments places this provider in the 95th percentile of 646 family practice providers in Texas.

See all family practice providers in Texas

Medicare billing

Part B allowed, 2024
$45,597
Medicare patients
184
Services billed
575

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban16$16,540
Breo ElliptaFluticasone/Vilanterol13$6,005
JardianceEmpagliflozin11$5,507
SynthroidLevothyroxine Sodium12$574
Rosuvastatin Calcium58$497
Atorvastatin Calcium66$359
Metoprolol Succinate24$328
Levothyroxine Sodium54$307
Lisinopril63$288
Albuterol Sulfate HfaAlbuterol Sulfate23$283
Losartan Potassium36$262
Trazodone Hcl32$259
Oxybutynin Chloride ErOxybutynin Chloride13$249
Duloxetine Hcl11$213
Buspirone Hcl14$201

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$16$16,54016 claims
GSKBreo Ellipta$29$6,00513 claims
Boehringer IngelheimJardiance$63$5,50711 claims
AbbVieSynthroid$197$57412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 646 family practice providers in Texas.

Other family practice in Plano

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →